Ironwood Pharma Files 8-K on Q4 Results & Financial Condition

TL;DR

**Ironwood Pharma just dropped an 8-K on their financial results, keep an eye out for the actual numbers!**

AI Summary

IRONWOOD PHARMACEUTICALS, INC. filed an 8-K on February 15, 2024, reporting on "Results of Operations and Financial Condition" and "Financial Statements and Exhibits." The earliest event reported also occurred on February 15, 2024. This standard filing informs investors about the company's recent financial performance and provides required disclosures.

Why It Matters

This filing signals that IRONWOOD PHARMACEUTICALS, INC. is disclosing its latest financial performance, which is crucial for investors to assess the company's health and future prospects. It provides transparency on the company's operational results.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial results and does not inherently present new risks without the specific financial data, which is not included in this snippet.

Key Players & Entities

• IRONWOOD PHARMACEUTICALS, INC. (company) — registrant
• February 15, 2024 (date) — date of report and earliest event reported
• 001-34620 (other) — Commission File Number
• 04-3404176 (other) — I.R.S. Employer Identification Number
• Boston (location) — city of principal executive offices
• Massachusetts (location) — state of principal executive offices
• 02110 (other) — zip code of principal executive offices

FAQ

Key Financial Figures

• $0.001 — ich registered Class A common stock, $0.001 par value IRWD Nasdaq Global Select M

Filing Documents

• tm246124d1_8k.htm (8-K) — 28KB
• tm246124d1_ex99-1.htm (EX-99.1) — 272KB
• tm246124d1_ex99-1img01.jpg (GRAPHIC) — 15KB
• 0001104659-24-024345.txt ( ) — 521KB
• irwd-20240215.xsd (EX-101.SCH) — 3KB
• irwd-20240215_lab.xml (EX-101.LAB) — 33KB
• irwd-20240215_pre.xml (EX-101.PRE) — 22KB
• tm246124d1_8k_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 15, 2024, Ironwood Pharmaceuticals, Inc. issued a press release containing an update on its recent business activities as well as those for the quarter and year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Ironwood Pharmaceuticals, Inc. Press Release dated February 15, 2024 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ironwood Pharmaceuticals, Inc. Dated: February 15, 2024 By: /s/ Sravan K. Emany Name: Sravan K. Emany Title: Senior Vice President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR